Advertisement
Advertisement
U.S. markets open in 8 hours 53 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Gracell Biotechnologies Inc. (GRCL)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
3.5200+0.0500 (+1.44%)
At close: 04:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Inside Bar (Bearish)

Inside Bar (Bearish)

Previous Close3.4700
Open3.4300
Bid0.0000 x 800
Ask0.0000 x 900
Day's Range3.1000 - 3.5900
52 Week Range1.6800 - 15.0000
Volume23,366
Avg. Volume69,485
Market Cap238.213M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.1340
Earnings DateAug 15, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.67
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for GRCL

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Gracell Biotechnologies Inc.
    Analyst Report: Gilead Sciences, Inc.Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
    Rating
    Fair Value
    Economic Moat
    18 days agoMorningstar
View more
  • PR Newswire

    Gracell Biotechnologies to Participate in Three Upcoming Investor Conferences

    Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that the management team will participate in and attend one-on-one meetings at three investor conferences in September 2022 as follows:

  • PR Newswire

    Gracell Biotechnologies to Participate in Four Upcoming Investor Conferences

    Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that the management team will participate in and attend one-on-one meetings at four investor conferences in September 2022 as follows:

  • GlobeNewswire

    Gracell Biotechnologies Reports Second Quarter 2022 Unaudited Financial Results and Provides Corporate Update

    Presented updated clinical data from an investigator-initiated trial (IIT) evaluating FasTCAR GC012F for the treatment of relapsed/refractory multiple myeloma (r/r MM) at ASCO and EHA 2022, which underscored the deep response with a 100% MRD negativity ratePresented first-in-human data of GC012F in relapsed/refractory B-cell Non-Hodgkin’s lymphomas (r/r B-NHL) at EHA 2022Presented updated results from an IIT evaluating allogeneic TruUCAR GC502 in relapsed/refractory B-cell acute lymphoblastic le

Advertisement
Advertisement